Cofrogliptin vs Evogliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Cofrogliptin
Marketed by Haisco Pharmaceutical Group
NCT04556851 · Phase 3 · completed
This randomized, double-blind, placebo-controlled trial enrolled 476 patients and measured change in HbA1c, a standard efficacy measure in diabetes, at 24 weeks. Both HSK7653 doses lowered HbA1c significantly more than placebo (p<0.0001), meeting the trial's primary goal.
Next expected readout: June 2027 · NCT07122102 (registry estimate)
Reported efficacy
HbA1c Change From Baseline at Week 24 (Baseline and week 24): HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin (met)
Result source: NCT04564872
Evogliptin · Suganon
Marketed by Dong-A ST and partners
NCT02949193 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial (n=222) comparing evogliptin against sitagliptin, both added to metformin. The prespecified non-inferiority comparison for the primary endpoint, HbA1c change at 24 weeks, was met: the between-group difference and its confidence interval stayed within the non-inferiority range.
Reported efficacy
Change from baseline in HbA1c (%) After 24 weeks: Change in HbA1c from baseline: at week 24, LS mean difference evogliptin vs placebo -0.65% (95% CI -0.79 to -0.51, P<0.0001); at week 52, evogliptin -0.59% vs placebo -0.04% (LS mean difference -0.55%, 95% CI -0.71 to -0.39, P<0.0001) (met)
Result source: NCT04170998
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Cofrogliptin | Evogliptin |
|---|---|---|
| HbA1c, change | -1.0% vs -1.1%avs linagliptin 5 mgNCT045648721 other result
| -0.2% vs 0.1%a−0.3 vs placeboNCT029465412 other results
|
| Body weight, change (kg) | —Not posted · NCT04564872 | —Not posted · NCT02949193 |
| HbA1c below 7% | —Not posted · NCT04564872 | —Not posted · NCT02949193 |
| Fasting plasma glucose, change | —Not posted · NCT04564872 | —Not posted · NCT02949193 |
| 3-point MACE (% with event) | —Not posted · NCT04564872 | —Not posted · NCT02949193 |
HbA1c, change
- Cofrogliptin
- -1.0% vs -1.1%avs linagliptin 5 mgNCT04564872
1 other result
- -1.0% vs -1.1% NCT04564872
- Evogliptin
- -0.2% vs 0.1%a−0.3 vs placeboNCT02946541
2 other results
- -0.6% vs -0.0% NCT04170998
- -0.6% vs -0.7% NCT02949193
Body weight, change (kg)
- Cofrogliptin
- —Not posted · NCT04564872
- Evogliptin
- —Not posted · NCT02949193
HbA1c below 7%
- Cofrogliptin
- —Not posted · NCT04564872
- Evogliptin
- —Not posted · NCT02949193
Fasting plasma glucose, change
- Cofrogliptin
- —Not posted · NCT04564872
- Evogliptin
- —Not posted · NCT02949193
3-point MACE (% with event)
- Cofrogliptin
- —Not posted · NCT04564872
- Evogliptin
- —Not posted · NCT02949193
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint
Coverage. Cofrogliptin: 1 of 1 rows · Evogliptin: 1 of 1 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Cofrogliptin Rows use multiple source trials | Evogliptin Rows use multiple source trials |
|---|---|---|
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.59% @ 24wk25 mga,b,c NCT04556851 · Phase 3 · sponsor-reported, not registry data show 1 more dose-0.63% @ 24wkcofrogliptin (HSK7653) 10 mg NCT04556851 · Phase 3 · sponsor-reported, not registry data | -0.65% @ 24wkb,c NCT04170998 · Phase 3 · sponsor-reported, not registry data |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cofrogliptin's landscape · Evogliptin's landscape